Transcatheter Aortic Valve Replacement
The New Gold Standard for Aortic Valve Replacement in Elderly Patients
What is the evidence for TAVR?
Five-Year Outcomes For High-Risk Sapien Patients Demonstrate Equivalence To Surgery, Durable Valve PerformanceTransforming Aortic Valve Replacement Therapy
Transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 valve demonstrated 75% lower rates of 30-day all-cause mortality and disabling stroke compared to surgery in intermediate-risk patients.†